Trial Profile
A Phase 2a Randomized, Blinded, Placebo-controlled Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of MEDI6012 in Subjects With Stable Atherosclerotic Cardiovascular Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs MEDI 6012 (Primary)
- Indications Atherosclerosis; Cardiovascular disorders
- Focus Adverse reactions; Therapeutic Use
- Sponsors MedImmune
- 29 Aug 2018 Primary results of this study presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology.
- 20 Aug 2018 According to AstraZeneca media release, data from this trial will be prestentd at the European Society of Cardiology (ESC) Congress .
- 29 Nov 2017 Status changed from recruiting to completed.